Wedbush Analysts Reduce Earnings Estimates for Chimerix

Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Equities research analysts at Wedbush lowered their Q4 2025 EPS estimates for Chimerix in a research note issued to investors on Tuesday, December 10th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings per share of ($0.28) for the quarter, down from their previous forecast of $0.28. Wedbush has a "Outperform" rating and a $6.00 price objective on the stock. The consensus estimate for Chimerix's current full-year earnings is ($0.99) per share. Wedbush also issued estimates for Chimerix's FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.06) EPS and FY2028 earnings at $0.47 EPS.

CMRX has been the topic of several other reports. HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of Chimerix in a report on Wednesday. StockNews.com raised Chimerix from a "sell" rating to a "hold" rating in a research report on Wednesday, August 21st.

Chimerix Stock Performance

NASDAQ CMRX traded up $0.02 on Friday, reaching $2.96. The stock had a trading volume of 2,158,256 shares, compared to its average volume of 1,250,414. The firm has a fifty day moving average of $1.03 and a two-hundred day moving average of $0.94. Chimerix has a 1-year low of $0.75 and a 1-year high of $3.39.

Hedge Funds Weigh In On Chimerix

A number of hedge funds have recently modified their holdings of the business. Valeo Financial Advisors LLC lifted its stake in shares of Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 69,505 shares during the period. Marshall Wace LLP bought a new stake in shares of Chimerix in the 2nd quarter valued at $137,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock worth $321,000 after acquiring an additional 138,098 shares during the period. Institutional investors and hedge funds own 45.42% of the company's stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.